882 related articles for article (PubMed ID: 25574968)
21. [Density and SUV ratios from PET/CT in the detection of mediastinal lymph node metastasis in non-small cell lung cancer].
Shao T; Yu L; Li Y; Chen M
Zhongguo Fei Ai Za Zhi; 2015 Mar; 18(3):155-60. PubMed ID: 25800571
[TBL] [Abstract][Full Text] [Related]
22. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.
Sommer G; Wiese M; Winter L; Lenz C; Klarhöfer M; Forrer F; Lardinois D; Bremerich J
Eur Radiol; 2012 Dec; 22(12):2859-67. PubMed ID: 22772365
[TBL] [Abstract][Full Text] [Related]
23. Prediction of true-negative lymph node metastasis in clinical IA non-small cell lung cancer by measuring standardized uptake values on positron emission tomography.
Takenaka T; Yano T; Morodomi Y; Ito K; Miura N; Kawano D; Shoji F; Baba S; Abe K; Honda H; Maehara Y
Surg Today; 2012 Oct; 42(10):934-9. PubMed ID: 22864936
[TBL] [Abstract][Full Text] [Related]
24. Correlation between apparent diffusion coefficients on diffusion-weighted MRI and standardized uptake value on FDG-PET/CT in pancreatic adenocarcinoma.
Sakane M; Tatsumi M; Kim T; Hori M; Onishi H; Nakamoto A; Eguchi H; Nagano H; Wakasa K; Hatazawa J; Tomiyama N
Acta Radiol; 2015 Sep; 56(9):1034-41. PubMed ID: 25267921
[TBL] [Abstract][Full Text] [Related]
25. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
[TBL] [Abstract][Full Text] [Related]
26. Prospective Correlation of Prognostic Immunohistochemical Markers With SUV and ADC Derived From Dedicated Hybrid Breast 18F-FDG PET/MRI in Women With Newly Diagnosed Breast Cancer.
Morawitz J; Kirchner J; Martin O; Bruckmann NM; Dietzel F; Li Y; Rischpler C; Herrmann K; Umutlu L; Bittner AK; Mohrmann S; Ingenwerth M; Häberle L; Esposito I; Antoch G; Buchbender C; Sawicki LM
Clin Nucl Med; 2021 Mar; 46(3):201-205. PubMed ID: 33351505
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
[TBL] [Abstract][Full Text] [Related]
28. N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT.
Ohno Y; Koyama H; Yoshikawa T; Nishio M; Aoyama N; Onishi Y; Takenaka D; Matsumoto S; Maniwa Y; Nishio W; Nishimura Y; Itoh T; Sugimura K
Radiology; 2011 Nov; 261(2):605-15. PubMed ID: 21926377
[TBL] [Abstract][Full Text] [Related]
29. Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer.
Fasmer KE; Gulati A; Dybvik JA; Ytre-Hauge S; Salvesen Ø; Trovik J; Krakstad C; Haldorsen IS
Eur Radiol; 2020 May; 30(5):2443-2453. PubMed ID: 32034487
[TBL] [Abstract][Full Text] [Related]
30. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
31. Use of maximum standardized uptake value on fluorodeoxyglucose positron-emission tomography in predicting lymph node involvement in patients with primary non-small cell lung cancer.
Muto J; Hida Y; Kaga K; Ohtaka K; Okamoto S; Tamaki N; Nakada-Kubota R; Hirano S; Matsui Y
Anticancer Res; 2014 Feb; 34(2):805-10. PubMed ID: 24511016
[TBL] [Abstract][Full Text] [Related]
32. Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer.
Nishiyama Y; Yamamoto Y; Kimura N; Ishikawa S; Sasakawa Y; Ohkawa M
Ann Nucl Med; 2008 May; 22(4):245-50. PubMed ID: 18535874
[TBL] [Abstract][Full Text] [Related]
33. Hybrid imaging for detection of carcinoma of unknown primary: A preliminary comparison trial of whole-body PET/MRI versus PET/CT.
Ruhlmann V; Ruhlmann M; Bellendorf A; Grueneisen J; Sawicki LM; Grafe H; Forsting M; Bockisch A; Umutlu L
Eur J Radiol; 2016 Nov; 85(11):1941-1947. PubMed ID: 27776644
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
35. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).
Guhlmann A; Storck M; Kotzerke J; Moog F; Sunder-Plassmann L; Reske SN
Thorax; 1997 May; 52(5):438-41. PubMed ID: 9176535
[TBL] [Abstract][Full Text] [Related]
36. Ratio between maximum standardized uptake value of N1 lymph nodes and tumor predicts N2 disease in patients with non-small cell lung cancer in 18F-FDG PET-CT scan.
Honguero Martínez AF; García Jiménez MD; García Vicente A; López-Torres Hidalgo J; Colon MJ; van Gómez López O; Soriano Castrejón ÁM; León Atance P
Rev Esp Med Nucl Imagen Mol; 2016; 35(3):159-64. PubMed ID: 26514322
[TBL] [Abstract][Full Text] [Related]
37. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
[TBL] [Abstract][Full Text] [Related]
38. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
[TBL] [Abstract][Full Text] [Related]
39. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer.
Miccò M; Vargas HA; Burger IA; Kollmeier MA; Goldman DA; Park KJ; Abu-Rustum NR; Hricak H; Sala E
Eur J Radiol; 2014 Jul; 83(7):1169-1176. PubMed ID: 24767630
[TBL] [Abstract][Full Text] [Related]
40. Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?
Schaarschmidt BM; Grueneisen J; Stebner V; Klode J; Stoffels I; Umutlu L; Schadendorf D; Heusch P; Antoch G; Pöppel TD
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2093-2102. PubMed ID: 29876618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
